DK0988378T4 - En fremgangsmåde til in vitro molekylær udvikling af proteinfunktion - Google Patents

En fremgangsmåde til in vitro molekylær udvikling af proteinfunktion

Info

Publication number
DK0988378T4
DK0988378T4 DK98901380T DK98901380T DK0988378T4 DK 0988378 T4 DK0988378 T4 DK 0988378T4 DK 98901380 T DK98901380 T DK 98901380T DK 98901380 T DK98901380 T DK 98901380T DK 0988378 T4 DK0988378 T4 DK 0988378T4
Authority
DK
Denmark
Prior art keywords
protein function
desired characteristics
variant
protein
scaffold
Prior art date
Application number
DK98901380T
Other languages
English (en)
Other versions
DK0988378T3 (da
Inventor
Ulf Hans Eskil Soederlind
Carl Arne Krister Borrebaeck
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10806508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0988378(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of DK0988378T3 publication Critical patent/DK0988378T3/da
Application granted granted Critical
Publication of DK0988378T4 publication Critical patent/DK0988378T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98901380T 1997-01-24 1998-01-26 En fremgangsmåde til in vitro molekylær udvikling af proteinfunktion DK0988378T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9701425.2A GB9701425D0 (en) 1997-01-24 1997-01-24 A method for in vitro molecular evolution of protein function
PCT/GB1998/000219 WO1998032845A1 (en) 1997-01-24 1998-01-26 A method for in vitro molecular evolution of protein function

Publications (2)

Publication Number Publication Date
DK0988378T3 DK0988378T3 (da) 2004-01-26
DK0988378T4 true DK0988378T4 (da) 2009-12-14

Family

ID=10806508

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98901380T DK0988378T4 (da) 1997-01-24 1998-01-26 En fremgangsmåde til in vitro molekylær udvikling af proteinfunktion

Country Status (12)

Country Link
US (4) US6989250B2 (da)
EP (2) EP0988378B9 (da)
JP (1) JP3703499B2 (da)
AT (1) ATE255163T1 (da)
AU (1) AU745615B2 (da)
CA (1) CA2278585C (da)
DE (1) DE69820054T3 (da)
DK (1) DK0988378T4 (da)
ES (1) ES2212260T5 (da)
GB (1) GB9701425D0 (da)
PT (1) PT988378E (da)
WO (1) WO1998032845A1 (da)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DK0974111T3 (da) 1997-04-11 2003-04-22 California Inst Of Techn Apparat og metode til automatiseret design af proteiner
GB9712512D0 (en) 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
FR2782323B1 (fr) * 1998-08-12 2002-01-11 Proteus Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
US6991922B2 (en) 1998-08-12 2006-01-31 Proteus S.A. Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation
US6951719B1 (en) 1999-08-11 2005-10-04 Proteus S.A. Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained
AU774334B2 (en) * 1998-10-16 2004-06-24 Xencor Protein design automation for protein libraries
US20020048772A1 (en) 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
EP1073710A4 (en) * 1999-02-04 2007-12-19 Verenium Corp NON-STOCHASTIC DEVELOPMENT OF GENETIC VACCINES AND ENZYMES
AU3879300A (en) * 1999-03-09 2000-09-28 Diversa Corporation End selection in directed evolution
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1118663A1 (en) 2000-01-07 2001-07-25 Universiteit Utrecht Nucleic acids encoding chemotaxis inhibitory polypeptides
EP1621617A1 (en) * 2000-02-10 2006-02-01 Xencor, Inc. Protein design automation for protein libraries
EP1255826B1 (en) * 2000-02-10 2005-09-14 Xencor Protein design automation for protein libraries
AU2001241939A1 (en) * 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US6994963B1 (en) 2000-07-10 2006-02-07 Ambion, Inc. Methods for recombinatorial nucleic acid synthesis
DE60143959D1 (de) 2000-08-25 2011-03-10 Basf Plant Science Gmbh En kodieren
WO2002022810A2 (en) * 2000-09-15 2002-03-21 Diversa Corporation Combinatorial screening of mixed populations of organisms
US20020155439A1 (en) * 2000-12-04 2002-10-24 Ana Rodriguez Method for generating a library of mutant oligonucleotides using the linear cyclic amplification reaction
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
EP1503321A3 (en) * 2001-08-10 2006-08-30 Xencor, Inc. Protein design automation for protein libraries
EP1456410A2 (en) * 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20030162209A1 (en) * 2001-12-19 2003-08-28 George Martin PCR based high throughput polypeptide screening
WO2003074678A2 (en) * 2002-03-01 2003-09-12 Dyax Corp. Modular recombinatorial display libraries
DK1504098T4 (da) 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
WO2004016811A2 (en) * 2002-08-19 2004-02-26 Danmarks Tekniske Universitet (Dtu) Methods and kit for genes shuffling using tagged primers
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
US20050053989A1 (en) * 2003-08-27 2005-03-10 Gil Sharon Libraries of recombinant chimeric proteins
GB0500703D0 (en) * 2005-01-14 2005-02-23 Bioinvent Int Ab Molecular biology method
US8076108B2 (en) * 2005-04-26 2011-12-13 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
BRPI0506047A (pt) * 2005-12-12 2007-10-02 Ubea método de obtenção de seqüências nucleotìdicas quiméricas e seqüência nucleotìdica quimérica
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
DK2102239T3 (da) 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
FR2910493B1 (fr) * 2006-12-20 2012-12-14 Bio Modeling Systems Ou Bmsystems Procede de diversification aleatoire d'une sequence genetique permettant de preserver l'identite de certains segments internes de ladite sequence genetique
EP2155789B1 (en) * 2007-05-01 2013-07-24 Research Development Foundation Immunoglobulin fc libraries
CA2693102C (en) 2007-07-31 2020-03-10 Verenium Corporation Tailored multi-site combinatorial assembly
JP2011504371A (ja) 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法
EP2130918A1 (de) * 2008-06-05 2009-12-09 C-Lecta GmbH Verfahren zur Erzeugung einer Varianten-Bibliothek von DNA-Sequenzen
US20090312196A1 (en) * 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
WO2010028347A2 (en) 2008-09-05 2010-03-11 President & Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
PT2373691T (pt) 2008-12-18 2019-05-08 Univ Vanderbilt Anticorpos anti-fxi e métodos de utilização
GB0903151D0 (en) 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
CN102459591B (zh) * 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
CN102549016B (zh) 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
CA2772298A1 (en) * 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
GB201105584D0 (en) 2011-04-01 2011-05-18 Imp Innovations Ltd Cancer methods
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
CA2825370A1 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
DK2726651T3 (da) 2011-06-28 2019-01-28 Codexis Inc Proteinvariantgeneration ved region shuffling
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
GB2495113A (en) 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
BR112014012590A8 (pt) 2011-11-23 2017-12-19 Igenica Inc Anticorpos anti-cd98 e métodos de uso dos mesmos
EP2785741A1 (en) 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
GB201300346D0 (en) 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2016130516A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
GB201814451D0 (en) 2018-09-05 2018-10-17 Valerie Nicholas Carl Kristoffer Methods
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
GB2584441A (en) 2019-06-03 2020-12-09 Fenomark Diagnostics Ab Medical uses, methods and uses
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
JP2023537470A (ja) 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
EP4214241A2 (en) 2020-09-15 2023-07-26 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
CN117396504A (zh) 2021-03-30 2024-01-12 拜耳公司 抗Sema3A抗体及其用途
CN118043352A (zh) 2021-09-02 2024-05-14 德国癌症研究中心公共法律基金会 副作用减少的抗cecam6抗体
US20230174995A1 (en) 2021-10-15 2023-06-08 Cytomx Therapeutics, Inc. Activatable polypeptide complex
KR20240115809A (ko) 2021-10-15 2024-07-26 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 폴리펩타이드 복합체
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
JP2025525530A (ja) 2022-07-15 2025-08-05 ヤンセン バイオテツク，インコーポレーテツド 抗原結合可変領域の改善された生物工学による対合のための材料及び方法
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5023171A (en) * 1989-08-10 1991-06-11 Mayo Foundation For Medical Education And Research Method for gene splicing by overlap extension using the polymerase chain reaction
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5573907A (en) * 1990-01-26 1996-11-12 Abbott Laboratories Detecting and amplifying target nucleic acids using exonucleolytic activity
US5387505A (en) * 1990-05-04 1995-02-07 Eastman Kodak Company Preparation and isolation of single-stranded biotinylated nucleic acids by heat avidin-biotin cleavage
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
EP0575410B1 (en) 1991-03-07 1999-05-19 BRADBURY, Andrew Raymon Morton Selection of specific proteins by a biological method
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
AU4782693A (en) * 1992-08-04 1994-03-03 British Technology Group Inc Method for design of novel proteins and proteins produced thereby
WO1994012632A1 (en) * 1992-11-27 1994-06-09 University College London Improvements in nucleic acid synthesis by pcr
AU6132994A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) * 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) * 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
DE69527835T2 (de) 1994-02-22 2003-04-10 Novozymes A/S, Bagsvaerd Methode zur herstellung einer variante eines lipolytischen enzymes
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
WO1996017056A1 (en) * 1994-12-02 1996-06-06 Institut Pasteur Hypermutagenesis
WO1996023899A1 (en) * 1995-02-01 1996-08-08 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
AR000862A1 (es) 1995-02-03 1997-08-06 Novozymes As Variantes de una ó-amilasa madre, un metodo para producir la misma, una estructura de adn y un vector de expresion, una celula transformada por dichaestructura de adn y vector, un aditivo para detergente, composicion detergente, una composicion para lavado de ropa y una composicion para la eliminacion del
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6110668A (en) 1996-10-07 2000-08-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Gene synthesis method
GB9701425D0 (en) * 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
GB9712512D0 (en) * 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5873458A (en) * 1997-09-12 1999-02-23 Kao; Kuo-Min Drawer type CD box structure

Also Published As

Publication number Publication date
DE69820054D1 (de) 2004-01-08
DK0988378T3 (da) 2004-01-26
PT988378E (pt) 2004-04-30
ES2212260T5 (es) 2010-04-05
EP0988378B9 (en) 2010-08-04
ATE255163T1 (de) 2003-12-15
US20110287486A1 (en) 2011-11-24
CA2278585C (en) 2011-09-27
EP0988378B1 (en) 2003-11-26
AU5771898A (en) 1998-08-18
ES2212260T3 (es) 2004-07-16
JP3703499B2 (ja) 2005-10-05
EP0988378B2 (en) 2009-11-18
CA2278585A1 (en) 1998-07-30
GB9701425D0 (en) 1997-03-12
US20050266451A1 (en) 2005-12-01
AU745615B2 (en) 2002-03-28
JP2001508660A (ja) 2001-07-03
US6989250B2 (en) 2006-01-24
US20080108507A1 (en) 2008-05-08
US7432083B2 (en) 2008-10-07
DE69820054T3 (de) 2010-05-06
EP1352959A1 (en) 2003-10-15
DE69820054T2 (de) 2004-09-09
US20030077613A1 (en) 2003-04-24
EP0988378A1 (en) 2000-03-29
WO1998032845A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
DK0988378T3 (da) En fremgangsmåde til in vitro molekylær udvikling af proteinfunktion
ATE315088T1 (de) Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
NO993953D0 (no) In vitro peptid- eller proteinekspresjonsbibliotek
DE69929019D1 (de) Mu-1, ein mitglied der zytokinrezeptor-familie
DE69730235D1 (de) Neuartige Verfahren und Zusammensetzungen zur Entdeckung von neuen multimerischen Molekülen, basierend auf einer kombinatorisichen Bibliothek
EP0777750A4 (en) HIGH SALES METHOD FOR DETECTING SEQUENCES OR GENETIC CHANGES IN NUCLEIC ACIDS
DE69710077D1 (de) Verfahren zur erkennung von verbindungen, die die interaktion von rna und rna-bindeproteinen beeinflussen
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
DK0866136T3 (da) Rekombinant bibliotekscreeningsfremgangsmåder
DK1015575T3 (da) Shuffling af heterologe DNA-sekvenser
WO1999006587A3 (en) Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
DK82093D0 (da) Fremgangsmaade til fremstilling af 6-chlor-7-iod-7-deazapuriner
DK0877752T3 (da) Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
DE69633563D1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
DK0898618T3 (da) Fremgangsmåde til tilvejebringelse af hidtil ukendte DNA-sekvenser
NO20054836L (no) Nogo-reseptorbindingsprotein
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
DK0641861T3 (da) Fremgangsmåde til fremstilling af hydrofobe polypeptider, proteiner eller peptider
EA200100160A1 (ru) Новые способы идентификации биомолекул лигандов и мишеней
WO2001088196A3 (en) Sequence based screening
DE60124954D1 (de) Mu-1, ein mitglied der cytokine rezeptor familie
DE69126592D1 (de) Nicht-lineare Peptide, die hydropatisch komplementär zu bekannten Aminosäuresequenzen sind, Verfahren zur Herstellung und Verwendung davon
DE69717601D1 (de) Verfahren zur analyse von nukleinsäure-wiederholungssequenzen
ATE410679T1 (de) Verfahren zur identifikation von antivirale substanzen